These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32390320)

  • 1. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia.
    Barra F; Della Corte L; Noberasco G; Foreste V; Riemma G; Di Filippo C; Bifulco G; Orsi A; Icardi G; Ferrero S
    J Obstet Gynaecol Res; 2020 Jul; 46(7):989-1006. PubMed ID: 32390320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
    Kechagias KS; Kalliala I; Bowden SJ; Athanasiou A; Paraskevaidi M; Paraskevaidis E; Dillner J; Nieminen P; Strander B; Sasieni P; Veroniki AA; Kyrgiou M
    BMJ; 2022 Aug; 378():e070135. PubMed ID: 35922074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol.
    Gonçalves CA; Lopes-Júnior LC; Nampo FK; Zilly A; Mayer PCM; Pereira-da-Silva G
    BMJ Open; 2019 Jul; 9(7):e026975. PubMed ID: 31320349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis.
    Eriksen DO; Jensen PT; Schroll JB; Hammer A
    Acta Obstet Gynecol Scand; 2022 Jun; 101(6):597-607. PubMed ID: 35470865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials.
    Ibrahim Khalil A; Zhang L; Muwonge R; Sauvaget C; Basu P
    BMJ Open; 2023 Oct; 13(10):e069616. PubMed ID: 37879679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus and vaccination in cervical cancer.
    Wang KL
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):352-62. PubMed ID: 18182340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial.
    van de Laar RLO; Hofhuis W; Duijnhoven RG; Polinder S; Melchers WJG; van Kemenade FJ; Bekkers RLM; Van Beekhuizen HJ
    BMC Cancer; 2020 Jun; 20(1):539. PubMed ID: 32517663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus as a target for management, prevention and therapy.
    Crosbie EJ; Kitchener HC
    Int J Hyperthermia; 2012; 28(6):478-88. PubMed ID: 22690976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
    Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
    Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group
    N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
    Corona Gutierrez CM; Tinoco A; Navarro T; Contreras ML; Cortes RR; Calzado P; Reyes L; Posternak R; Morosoli G; Verde ML; Rosales R
    Hum Gene Ther; 2004 May; 15(5):421-31. PubMed ID: 15144573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What should be known for the introduction of an HPV vaccine?].
    Muñoz N; Jacquard AC
    Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current research into novel therapeutic vaccines against cervical cancer.
    Cordeiro MN; De Lima RCP; Paolini F; Melo ARDS; Campos APF; Venuti A; De Freitas AC
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):365-376. PubMed ID: 29475377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of human papilloma virus infection with vaccines.
    Azam F; Shams-ul-Islam M
    J Pak Med Assoc; 2010 Aug; 60(8):676-81. PubMed ID: 20726203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016.
    Welby S; Rosillon D; Feng Y; Borys D
    Expert Rev Vaccines; 2022 Mar; 21(3):407-413. PubMed ID: 34939897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccines and adolescents.
    Kahn JA; Bernstein DI
    Curr Opin Obstet Gynecol; 2005 Oct; 17(5):476-82. PubMed ID: 16141761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions.
    Ma M; Zhu J; Yang Y; Wang X; Jin Y; Zhang J; Wu S
    Cancer Med; 2022 Mar; 11(6):1542-1552. PubMed ID: 34981653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.